Artivion Inc. (AORT) Insider Trading

Last 12 months

Insiders sold $20.7M and bought nothing on the open market.

24% of the selling was scheduled in advance under 10b5-1 plans. SVP, Clinical & MD Affair Marshall S. Stanton sold $2.13M on Nov 21, 2025, 51% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2025.

Net open-market

−$20.7M

0 buys · 46 sales

Under a 10b5-1 plan

24%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Mar 2025

Mar 5, 2025

Get an email when AORT's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 10	Andrew M Green SVP, Regulatory and Quality	SoldNo plan	11,480	$24.97	$287k	22%	Form 4
Sep 2 – 3	Andrew M Green SVP, Regulatory and Quality	SoldNo plan 2 parts	8,003	$27.04 average	$216k	13%	Form 4
Aug 19	James P Mackin President & CEO	SoldNo plan	70,000	$28.96	$2.03M	7.4%	Form 4
Aug 14	Andrew M Green SVP, Regulatory and Quality	SoldNo plan	616	$28.55	$18k	1.0%	Form 4
Aug 14	Lance A Berry EVP, COO, CFO & Treasurer	SoldNo plan	715	$28.55	$20k	0.3%	Form 4
Aug 12	Jean F Holloway SVP, General Counsel	SoldNo plan	977	$28.49	$28k	0.5%	Form 4
Jun 11	Andrew M Green SVP, Regulatory and Quality	Sold10b5-1 plan 2 parts	44,001	$20.70 average	$911k	42%	Form 4
Mar 3 – 4	Jean F Holloway SVP, General Counsel	SoldNo plan 2 parts	12,805	$37.93 average	$486k	6.5%	Form 4
Mar 3	Amy Horton VP, Chief Accounting Officer	SoldNo plan	901	$37.78	$34k	0.6%	Form 4
Mar 3	Marshall S. Stanton SVP, Clinical & MD Affair	SoldNo plan	2,149	$37.78	$81k	3.5%	Form 4
Mar 3	John E Davis Chief Commercial Officer	SoldNo plan	4,573	$37.78	$173k	1.9%	Form 4
Mar 3	Lance A Berry EVP, COO, CFO & Treasurer	SoldNo plan	6,316	$37.78	$239k	2.9%	Form 4
Mar 3	James P Mackin President & CEO	SoldNo plan	17,887	$37.78	$676k	1.9%	Form 4
Mar 2	Amy Horton VP, Chief Accounting Officer	SoldNo plan	641	$38.02	$24k	0.5%	Form 4
Mar 2	Marshall S. Stanton SVP, Clinical & MD Affair	SoldNo plan	1,513	$38.02	$58k	3.6%	Form 4
Mar 2	James P Mackin President & CEO	SoldNo plan	14,911	$38.02	$567k	1.7%	Form 4
Mar 2	Jean F Holloway SVP, General Counsel	SoldNo plan	2,183	$38.02	$83k	1.3%	Form 4
Mar 2	Lance A Berry EVP, COO, CFO & Treasurer	SoldNo plan	5,178	$38.02	$197k	2.9%	Form 4
Mar 2	John E Davis Chief Commercial Officer	SoldNo plan	2,784	$38.02	$106k	1.3%	Form 4
Feb 23 – 24	Amy Horton VP, Chief Accounting Officer	SoldNo plan 2 parts	2,561	$36.97 average	$95k	1.9%	Form 4
Feb 23 – 24	Marshall S. Stanton SVP, Clinical & MD Affair	SoldNo plan 2 parts	3,682	$36.94 average	$136k	8.1%	Form 4
Feb 23 – 24	Jean F Holloway SVP, General Counsel	SoldNo plan 2 parts	4,747	$36.92 average	$175k	2.7%	Form 4
Feb 23 – 24	James P Mackin President & CEO	SoldNo plan 2 parts	34,898	$36.83 average	$1.29M	3.9%	Form 4
Feb 23 – 24	Lance A Berry EVP, COO, CFO & Treasurer	SoldNo plan 2 parts	9,466	$36.69 average	$347k	5.0%	Form 4
Feb 23 – 24	John E Davis Chief Commercial Officer	SoldNo plan 2 parts	5,848	$36.92 average	$216k	2.7%	Form 4
Dec 15, 2025	John E Davis Chief Commercial Officer	SoldNo plan	5,000	$45.11	$226k	2.5%	Form 4
Dec 8, 2025	Amy Horton VP, Chief Accounting Officer	SoldNo plan	4,572	$44.42	$203k	3.4%	Form 4
Dec 3, 2025	James P Mackin President & CEO	Sold10b5-1 plan	30,921	$45.46	$1.41M	3.7%	Form 4
Dec 3, 2025	Jean F Holloway SVP, General Counsel	SoldNo plan 2 parts	7,315	$45.30 average	$331k	4.5%	Form 4
Dec 2, 2025	James P Mackin President & CEO	Sold10b5-1 plan	30,921	$45.56	$1.41M	3.7%	Form 4
Nov 21, 2025	Marshall S. Stanton SVP, Clinical & MD Affair	SoldNo plan 4 parts	47,376	$45.04 average	$2.13M	51%	Form 4
Nov 20, 2025	Marshall S. Stanton SVP, Clinical & MD Affair	SoldNo plan 3 parts	15,276	$44.18 average	$675k	25%	Form 4
Nov 18, 2025	Elizabeth A Hoff Director	SoldNo plan	4,200	$45.10	$189k	13%	Form 4
Nov 14, 2025 – Nov 17, 2025	Jean F Holloway SVP, General Counsel	Sold10b5-1 plan 2 parts	12,787	$45.09 average	$577k	7.3%	Form 4
Nov 14, 2025 – Nov 17, 2025	John E Davis Chief Commercial Officer	Sold10b5-1 plan 2 parts	12,787	$44.92 average	$574k	6.0%	Form 4
Nov 17, 2025	Amy Horton VP, Chief Accounting Officer	SoldNo plan	6,000	$45.73	$274k	4.2%	Form 4
Nov 13, 2025	Amy Horton VP, Chief Accounting Officer	SoldNo plan	3,482	$45.86	$160k	2.4%	Form 4
Nov 13, 2025	John E Davis Chief Commercial Officer	SoldNo plan	6,563	$45.86	$301k	3.2%	Form 4
Nov 13, 2025	James P Mackin President & CEO	SoldNo plan	34,210	$45.86	$1.57M	4.1%	Form 4
Nov 13, 2025	Jean F Holloway SVP, General Counsel	SoldNo plan	5,761	$45.86	$264k	3.4%	Form 4

Sep 10No plan
Andrew M Green
SVP, Regulatory and Quality · sold 11,480 at $24.97
$287k
22% of stake
Sep 2 – 3No plan
Andrew M Green
SVP, Regulatory and Quality · sold 8,003 at avg $27.04
$216k
13% of stake
Aug 19No plan
James P Mackin
President & CEO · sold 70,000 at $28.96
$2.03M
7.4% of stake
Aug 14No plan
Andrew M Green
SVP, Regulatory and Quality · sold 616 at $28.55
$18k
1.0% of stake
Aug 14No plan
Lance A Berry
EVP, COO, CFO & Treasurer · sold 715 at $28.55
$20k
0.3% of stake
Aug 12No plan
Jean F Holloway
SVP, General Counsel · sold 977 at $28.49
$28k
0.5% of stake
Jun 1110b5-1 plan
Andrew M Green
SVP, Regulatory and Quality · sold 44,001 at avg $20.70
$911k
42% of stake
Mar 3 – 4No plan
Jean F Holloway
SVP, General Counsel · sold 12,805 at avg $37.93
$486k
6.5% of stake
Mar 3No plan
Amy Horton
VP, Chief Accounting Officer · sold 901 at $37.78
$34k
0.6% of stake
Mar 3No plan
Marshall S. Stanton
SVP, Clinical & MD Affair · sold 2,149 at $37.78
$81k
3.5% of stake
Mar 3No plan
John E Davis
Chief Commercial Officer · sold 4,573 at $37.78
$173k
1.9% of stake
Mar 3No plan
Lance A Berry
EVP, COO, CFO & Treasurer · sold 6,316 at $37.78
$239k
2.9% of stake
Mar 3No plan
James P Mackin
President & CEO · sold 17,887 at $37.78
$676k
1.9% of stake
Mar 2No plan
Amy Horton
VP, Chief Accounting Officer · sold 641 at $38.02
$24k
0.5% of stake
Mar 2No plan
Marshall S. Stanton
SVP, Clinical & MD Affair · sold 1,513 at $38.02
$58k
3.6% of stake
Mar 2No plan
James P Mackin
President & CEO · sold 14,911 at $38.02
$567k
1.7% of stake
Mar 2No plan
Jean F Holloway
SVP, General Counsel · sold 2,183 at $38.02
$83k
1.3% of stake
Mar 2No plan
Lance A Berry
EVP, COO, CFO & Treasurer · sold 5,178 at $38.02
$197k
2.9% of stake
Mar 2No plan
John E Davis
Chief Commercial Officer · sold 2,784 at $38.02
$106k
1.3% of stake
Feb 23 – 24No plan
Amy Horton
VP, Chief Accounting Officer · sold 2,561 at avg $36.97
$95k
1.9% of stake
Feb 23 – 24No plan
Marshall S. Stanton
SVP, Clinical & MD Affair · sold 3,682 at avg $36.94
$136k
8.1% of stake
Feb 23 – 24No plan
Jean F Holloway
SVP, General Counsel · sold 4,747 at avg $36.92
$175k
2.7% of stake
Feb 23 – 24No plan
James P Mackin
President & CEO · sold 34,898 at avg $36.83
$1.29M
3.9% of stake
Feb 23 – 24No plan
Lance A Berry
EVP, COO, CFO & Treasurer · sold 9,466 at avg $36.69
$347k
5.0% of stake
Feb 23 – 24No plan
John E Davis
Chief Commercial Officer · sold 5,848 at avg $36.92
$216k
2.7% of stake
Dec 15, 2025No plan
John E Davis
Chief Commercial Officer · sold 5,000 at $45.11
$226k
2.5% of stake
Dec 8, 2025No plan
Amy Horton
VP, Chief Accounting Officer · sold 4,572 at $44.42
$203k
3.4% of stake
Dec 3, 202510b5-1 plan
James P Mackin
President & CEO · sold 30,921 at $45.46
$1.41M
3.7% of stake
Dec 3, 2025No plan
Jean F Holloway
SVP, General Counsel · sold 7,315 at avg $45.30
$331k
4.5% of stake
Dec 2, 202510b5-1 plan
James P Mackin
President & CEO · sold 30,921 at $45.56
$1.41M
3.7% of stake
Nov 21, 2025No plan
Marshall S. Stanton
SVP, Clinical & MD Affair · sold 47,376 at avg $45.04
$2.13M
51% of stake
Nov 20, 2025No plan
Marshall S. Stanton
SVP, Clinical & MD Affair · sold 15,276 at avg $44.18
$675k
25% of stake
Nov 18, 2025No plan
Elizabeth A Hoff
Director · sold 4,200 at $45.10
$189k
13% of stake
Nov 14, 2025 – Nov 17, 202510b5-1 plan
Jean F Holloway
SVP, General Counsel · sold 12,787 at avg $45.09
$577k
7.3% of stake
Nov 14, 2025 – Nov 17, 202510b5-1 plan
John E Davis
Chief Commercial Officer · sold 12,787 at avg $44.92
$574k
6.0% of stake
Nov 17, 2025No plan
Amy Horton
VP, Chief Accounting Officer · sold 6,000 at $45.73
$274k
4.2% of stake
Nov 13, 2025No plan
Amy Horton
VP, Chief Accounting Officer · sold 3,482 at $45.86
$160k
2.4% of stake
Nov 13, 2025No plan
John E Davis
Chief Commercial Officer · sold 6,563 at $45.86
$301k
3.2% of stake
Nov 13, 2025No plan
James P Mackin
President & CEO · sold 34,210 at $45.86
$1.57M
4.1% of stake
Nov 13, 2025No plan
Jean F Holloway
SVP, General Counsel · sold 5,761 at $45.86
$264k
3.4% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch AORT, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: Surgical & Medical Instruments & Apparatus

ARAYAccuray Incorporated

ATRCAtriCure, Inc.

BVSBioventus Inc.

MDXGMiMedx Group, Inc.

TCMDTactile Systems Technology Inc.

PRCTProcept BioRobotics Corporation

GKOSGlaukos Corporation

ANGOAngiodynamics Inc.

Spot a number that looks wrong? Check it in AORT's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing AORT

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.